A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen- positive patients: a prospective cohort study in China Y. Zhang,

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

بنام خداوند مهربان. دکتر نرگس نجفی دانشیار دانشگاه.

Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen–Positive Patients with Chronic Hepatitis B : A Randomized International Study of Entecavir.

Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10.

Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated.

Volume 67, Issue 2, Pages (August 2017)

Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10.

R. Cavallo Clinical Microbiology and Infection

Twelve years of dengue surveillance in Belgian travellers and significant increases in the number of cases in 2010 and 2013 J. Verschueren, L. Cnops,

Evolution of the incidence of hepatitis B virus infection and immunization rates in a large French cohort born between 1960 and 1994 C. Ramière, L. Roche,

Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience M.-C.

Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B

Intrahepatic hepatitis B virus replication and liver histology in subjects with occult hepatitis B infection D.K.-H. Wong, J. Fung, C.-K. Lee, W.-K.

Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.

Prediction of virological response by pretreatment hepatitis B virus reverse transcriptase quasispecies heterogeneity: the advantage of using next-generation.

Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis T. Steinmetz, N.

Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications T.-L. Liao, Y.-M.

Migrant health—a cause for concern?

The relationship between tumour necrosis factor-α gene polymorphism and susceptibility and clearance of the persistent hepatitis B virus infection in.

Hepatitis B and C virus-related carcinogenesis

Infectious causes of cancer: an evolving educational saga

Virological tools to diagnose and monitor hepatitis C virus infection

Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen–positive chronic.

Paradoxical immune reconstitution inflammatory syndrome associated with cryptococcal meningitis in China: a 5-year retrospective cohort study S. Yan,

Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective.

Hepatitis B virus basal core promoter/precore mutants and association with liver cirrhosis in children with chronic hepatitis B virus infection Y.W.

Volume 68, Issue 3, Pages (March 2018)

V.E. Nambudiri, R.C. Dwyer, C.A. Camargo, T.S. Kupper, D.J. Pallin

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C Chi–Jen Chu, Munira Hussain,

Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B W.-K. Seto, D. K.-H. Wong,

F. Li, P. Zhou, W. Deng, J. Wang, R. Mao, Y. Zhang, J. Li, J. Yu, F

A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match–control study M.-C. Tsai,

Validation of a treatment algorithm for orthopaedic implant-related infections with device-retention—results from a prospective observational cohort study

L. -W. Song, P. -G. Liu, C. -J. Liu, T. -Y. Zhang, X. -D. Cheng, H. -L

Comparison of respiratory virus shedding by conventional and molecular testing methods in patients with haematological malignancy L. Richardson, J. Brite,

Ming-Ling Chang, Yun-Fan Liaw Journal of Hepatology

Estimation of delay in detecting hepatitis C virus antibodies in pools compared to individual testing on seroconversion panels B. Sarov, L. Novack, N.

Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated.

C. Fabrizio, A. Procopio Clinical Microbiology and Infection

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Early invasive fungal infections and colonization in patients with cirrhosis admitted to the intensive care unit E. Theocharidou, B. Agarwal, G. Jeffrey,

Human infection with H9N2 avian influenza in northern China

A. Pierangeli, F. Cannella, C. Scagnolari, M. Gentile, I. Sciandra, G

Levofloxacin in the treatment of ventilator-associated pneumonia

J. Bodilsen, C. T. Brandt, A. Sharew, M. Dalager-Pedersen, T

Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus.

Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.

Hepatitis B and C virus-related carcinogenesis

Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected.

Continuous high-dose vancomycin combination therapy for methicillin-resistant staphylococcal prosthetic hip infection: a prospective cohort study V.

Volume 139, Issue 2, Pages (August 2010)

Systematic review of antibiotic consumption in acute care hospitals

EASL Clinical Practice Guidelines: Management of chronic hepatitis B

M. Daudin, P. Tattevin, B. Lelong, E. Flecher, S. Lavoué, C. Piau, A

Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection E. Knops, E. Heger Clinical Microbiology.

Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy L. Boglione,

H. Leblebicioglu, C. Eroglu Clinical Microbiology and Infection

Increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic.

Dynamics of hepatitis B virus quasispecies heterogeneity in association with nucleos(t)ide analogue treatment determined by MALDI-TOF MS M. Rybicka,

Increasing numbers of hospitalizations and deaths with mention of Clostridium difficile infection, north-eastern Italy, 2008–2013 U. Fedeli, E. Schievano,

Statin use and clinical outcomes among pneumonia patients

Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients H.-Y. Pan, H.-Y. Pan,

Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis

Virology: a scientific discipline facing new challenges

Clinical Gastroenterology and Hepatology

J.L. Balcázar Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients D. He, S. Guo, P. Zhu, S. Tao, M. Li,

Presentation transcript:

A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen- positive patients: a prospective cohort study in China Y. Zhang, P. Hu, X. Qi, H. Ren, R.-C. Mao, J.-M. Zhang Clinical Microbiology and Infection Volume 22, Issue 3, Pages 287.e1-287.e9 (March 2016) DOI: 10.1016/j.cmi.2015.10.024 Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 1 Abbreviations: LdT, telbivudine; ETV, entecavir; NA, nucleos(t)ide analogue. Clinical Microbiology and Infection 2016 22, 287.e1-287.e9DOI: (10.1016/j.cmi.2015.10.024) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 2 Effects of telbivudine (LdT) and entecavir (ETV) on hepatitis B virus (HBV) DNA and alanine transaminase (ALT) levels. (a) Cumulative rates of HBV DNA undetectability and (b) ALT normalization in telbivudine-and entecavir-treated HBV e antigen (HBeAg)-positive patients after 240 weeks. Clinical Microbiology and Infection 2016 22, 287.e1-287.e9DOI: (10.1016/j.cmi.2015.10.024) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 3 Effects of telbivudine (LdT) and entecavir (ETV) on viral breakthrough. (a) The cumulative viral breakthrough rates were estimated by the Kaplan–Meier method; and (b) shown at 48, 96, 144, 192 and 240 weeks. Clinical Microbiology and Infection 2016 22, 287.e1-287.e9DOI: (10.1016/j.cmi.2015.10.024) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 4 Effects of telbivudine (LdT) and entecavir (ETV) on hepatitis B e antigen (HBeAg) seroconversion. (a)The cumulative HBeAg seroconversion rates were estimated by the Kaplan–Meier method; and (b) shown at 48, 96, 144, 192 and 240 weeks. Clinical Microbiology and Infection 2016 22, 287.e1-287.e9DOI: (10.1016/j.cmi.2015.10.024) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 5 Hepatitis B e antigen (HBeAg) seroconversion in patient sub-groups, stratified by alanine transaminase (ALT) levels. Cumulative HBeAg seroconversion rates at 48, 96, 144, 192 and 240 weeks are shown for patients who had ALT five or more times the upper limit of normal (ULN) or ALT less than five time the ULN at baseline and were treated with (a) telbivudine (LdT) or (b) entecavir (ETV). Clinical Microbiology and Infection 2016 22, 287.e1-287.e9DOI: (10.1016/j.cmi.2015.10.024) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

FIG. S1. Cumulative hepatitis B e antigen (HBeAg) seroconversion rates in matched patient sub-groups. Patients matched for age, baseline serum alanine transaminase (ALT), and hepatitis B viral DNA levels were selected from the telbivudine (LDT)- and entecavir (ETV)-treated HBeAg-positive patients (n = 56 from each group). (a) Cumulative HBeAg seroconversion rates after 240 weeks, estimated by the Kaplan–Meier method; (b) cumulative HBeAg seroconversion rates at 48, 96, 144, 192 and 240 weeks.1 Clinical Microbiology and Infection 2016 22, 287.e1-287.e9DOI: (10.1016/j.cmi.2015.10.024) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

FIG. S2. Changes in creatine kinase (CK) and estimated glomerular filtration rate (eGFR) in patients with chronic hepatitis B (CHB) after telbivudine (LdT) and entecavir (ETV) treatment. (a) Comparison of CK elevations between the telbivudine group and entecavir group and (b) eGFR changes between the two groups.2 Clinical Microbiology and Infection 2016 22, 287.e1-287.e9DOI: (10.1016/j.cmi.2015.10.024) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

FIG. S3. Relationship between early virological response and cumulative hepatitis B e antigen (HBeAg) seroconversion rates at 48, 96, 144, 192 and 240 weeks in (a) the telbivudine (LdT) group or (b) the entecavir (ETV) group (early virological response: hepatitis B virus DNA <100 IU/mL at week 24 after nucleos(t)ide analogue therapy).3 Clinical Microbiology and Infection 2016 22, 287.e1-287.e9DOI: (10.1016/j.cmi.2015.10.024) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

FIG. S4. Relationship between early biochemical response and cumulative hepatitis B e antigen (HBeAg) seroconversion rates at 48, 96, 144, 192 and 240 weeks in (a) the telbivudine (LdT) group or (b) the entecavir (ETV) group (early biochemical response: alanine transaminase normalization at week 24 after nucleos(t)ide analogue therapy).4 Clinical Microbiology and Infection 2016 22, 287.e1-287.e9DOI: (10.1016/j.cmi.2015.10.024) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions